Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Rating Increased to Hold at StockNews.com

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Monday.

Other analysts have also issued research reports about the stock. Maxim Group raised their price target on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, March 19th. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Actinium Pharmaceuticals in a report on Monday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 price objective on shares of Actinium Pharmaceuticals in a report on Monday, April 1st. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $25.72.

Actinium Pharmaceuticals Trading Up 8.2 %

Shares of Actinium Pharmaceuticals stock traded up $0.56 during trading on Monday, hitting $7.43. The stock had a trading volume of 244,842 shares, compared to its average volume of 322,240. Actinium Pharmaceuticals has a 12 month low of $4.00 and a 12 month high of $9.86. The firm has a market capitalization of $218.44 million, a PE ratio of -4.06 and a beta of 0.01.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its earnings results on Friday, March 29th. The biotechnology company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.21. The business had revenue of $0.08 million for the quarter. As a group, sell-side analysts predict that Actinium Pharmaceuticals will post -1.87 earnings per share for the current fiscal year.

Institutional Trading of Actinium Pharmaceuticals

A number of large investors have recently made changes to their positions in ATNM. Brandywine Global Investment Management LLC acquired a new stake in Actinium Pharmaceuticals in the third quarter valued at $1,033,000. Sanders Morris Harris LLC purchased a new stake in shares of Actinium Pharmaceuticals in the first quarter valued at $78,000. Finally, Creative Financial Designs Inc. ADV grew its holdings in Actinium Pharmaceuticals by 19.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 3,175 shares during the period. 27.50% of the stock is owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.